Cartesian Therapeutics, Inc. Amortization of Debt Issuance Costs and Discounts
Cartesian Therapeutics, Inc. (RNAC) reported Amortization of Debt Issuance Costs and Discounts of -$110.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2023-03-02
- Cartesian Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was -$110.00K.
- Cartesian Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2021 was $0.00.
- Cartesian Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2020 was $0.00.
| Period end | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|
| 2022-12-31 | -$110.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |